Armata Announces Q3 Financial Results and Prepares for AP-SA02 Phase 3 Study
The biotech company reported Q3 financial results and confirmed it is advancing operational preparations and manufacturing for its Phase 3 pivotal study of bacteriophage candidate AP-SA02.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed